Allogene Therapeutics Inc... (ALLO)
NASDAQ: ALLO
· Real-Time Price · USD
1.15
0.04 (3.60%)
At close: Sep 05, 2025, 3:59 PM
1.16
0.85%
After-hours: Sep 05, 2025, 07:04 PM EDT
3.60% (1D)
| Bid | 1.11 |
| Market Cap | 255.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -236.91M |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -1.05 |
| Forward PE | -1.24 |
| Analyst | Buy |
| Ask | 1.19 |
| Volume | 2,286,555 |
| Avg. Volume (20D) | 4,048,838 |
| Open | 1.10 |
| Previous Close | 1.11 |
| Day's Range | 1.10 - 1.18 |
| 52-Week Range | 0.86 - 3.78 |
| Beta | 0.36 |
About ALLO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALLO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALLO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Allogene Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+8.55%
Allogene Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
3 months ago
-15.68%
Allogene Therapeutics shares are trading lower after the company reported Q1 financial results. Also, Baird and Oppenheimer lowered their respective price targets on the stock.
3 weeks ago · seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call TranscriptAllogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy ...
2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Sells 168,152 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Squarepoint Ops LLC cut its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 89.2% during the fourth quarter, according to the company in its most recent disclosu...